ABS Direct Equity Fund’s Jazz Pharmaceuticals JAZZ Stock Holding History

ABS Direct Equity Fund’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$187K	Buy	+900	New	+$157K	0.14%	83

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ABS Direct Equity Fund's JAZZ Position: Q1 2026 in Review

ABS Direct Equity Fund opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 900 shares worth $187K. The stake represents 0.14% of the portfolio and ranks #83 among its holdings.

570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

ABS Direct Equity Fund held 900 shares of Jazz Pharmaceuticals worth $187K as of Q1 2026.
Jazz Pharmaceuticals was a new ABS Direct Equity Fund position in Q1 2026.
Jazz Pharmaceuticals made up 0.14% of ABS Direct Equity Fund's portfolio in Q1 2026, its #83 holding.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on ABS Direct Equity Fund's 13F filing for Q1 2026, filed 15 May 2026.